Most likely Gide ("Croyez ceux qui cherchent la vérité, doutez de ceux qui la trouvent", "Believe those who seek Truth, doubt those who find it") and not Voltaire ;)
Voltaire was generally more subtle: "un bon mot ne prouve rien", a witty saying proves nothing, as he'd say.
It is rare, and is probably due to a combination of green tea and weight loss. However, the effects are catastrophic, and it worth pointing out before someone decides to use tea extracts to "protect" their liver.
There are more cases that appears through cursory review of the literature, as most go unreported/unpublished. I have seen one case myself, and the person barely survived.
Beware that green tea supplements have been associated with very sever liver damage. Even though most survive, they often require prolonged intensive care, with attending complications, muscle wasting, etc.
I also strongly recommend using an iron gall ink (Platinum makes a few; another very good one is http://www.registrarsink.co.uk). Those inks are very easy to work with, even on the crappiest paper, and are quite resistant to UV, water, and other hasards.
Pharma and rich greedy doctors are an easy target, but reality is (always) more complicated.
Pyridoxine/doxylamine is nothing new, and was released in the USA in the fifties, and withdrawn from the market in the early eighties due to numerous (baseless) lawsuit alleging it caused birth defects. This formulation is known as Diclectin in Canada, where there were no lawsuits (and thus, no withdrawal), and it costs pennies.
The medication was reintroduced in the USA about 10 years ago as Diclegis by another manufacturer, and Bonjesta is essentially Dicglesis with improved pharmacokinetics (whether this matters clinically is another question).
It is interesting to note that Bonjesta is produced by Duchesnay USA, which is owned by the Canadian company Duchesnay, which markets Diclectin here in Canada. I suspect that no American company is willing to risk a lawsuit *even* at the current seemingly absurdly high pricing. Duchesnay USA is essentially a mono-pill company, and I imagine that the strategy is that they're willing to go under in case of a class action.
You're assuming that more data will reveal a hidden pattern, but the fact is that most data, and especially most of the easily collectable data is useless junk.
Diagnosis is based on imperfect data with very high noise-to-signal ratio, and with auditory (patient's history), visual and tactile inputs. Treatment often need to be tailored for each patients unique needs, goals, and co-existing diseases.
The quote is from Pascal: "Je n'ai fait celle-ci plus longue que parce que je n'ai pas eu le loisir de la faire plus courte", "I made this one [the letter] longer, since I didn't have the leisure to make it shorter".
Garbage statistics will not get better if you insist on some arbitrary fragility index threshold (and no accepted threshold of an "acceptable" fragility index does exist to the best of my knowledge). Also, using a lower alpha will automatically give you a larger sample size, without invoking a completely superfluous fragility index.
Nobody should interpret clinical studies in isolation; they only have meaning in a "qualitative" Bayesian framework which integrates physiological plausibility, other available trials, and risk/benefit ratio. The fragility index only muddies waters, as clinicians misinterpret it even more frequently than the much maligned p-value, all while not delivering any more information than the p-value itself.
The fragility index is essentially a repackaged p-value, and serves only to introduce even more confusion on the top of this already often misunderstood metric. See very good discussion here: https://academic.oup.com/eurheartj/article/38/5/346/2422087
Also, trials are generally designed to recruit the minimal number of patients we can get away with, and this is done for good reason (cost, feasibility, and the ethical concern of "using" the lowest possible number of human beings, while allowing any beneficial treatment to benefit the most as soon as possible). If someone's then pointing out that this trial is "fragile" -- well, yes, it was designed so in advance! Would you propose to expose 100 more patients to an inferior treatment just to improve your fragility index?
Probably significant. In this population of very severe patients, mortality was "only" 25% in patients managed without proning. Compare with mortalities around ~50% reported early into the pandemic in comparable populations.
Obviously difficult to say which part comes from patients presenting later in their disease course, doctors, nurses and respiratory therapists being overwhelmed with sudden influx of cases, and so forth -- and which can be directly attributed to premature and unwarranted intubation.
> It is not known whether brain can be brought back at all once all signals stop.
This is incorrect. In a brain-dead patient, the isoelectric EEG serves to demonstrate the absence of brain activity despite adequate perfusion and absence of sedation, i.e, even though the computer is plugged in and you've pressed the start button, nothing happens, and thus, nothing is likely to happen in the future.
Isoelectric EEG can be induced with propofol and barbiturates, either voluntarily (refractory epilepsy) or involuntarily (anesthesia), without any obvious ill effects once the sedation is off.
An alternative explanation is that of "viral interference"[1,2], i.e., the most transmissible virus boosting up viral immunity in the population, and precluding transmission of the less transmissible/fit virus
Voltaire was generally more subtle: "un bon mot ne prouve rien", a witty saying proves nothing, as he'd say.